High-Dose ribof lavin for migraine prophylaxis in children: A double-blind, randomized, placebo-controlled trial

Journal of Child Neurology

Volumn 23, Issue 11, 2008, Pages 1300-1304

  MacLennan, Suzanna C ^a,b   Wade, Fiona M ^b   Forrest, Katharine M L ^b   Ratanayake, Pyara D ^b   Fagan, Elizabeth ^b   Antony, Jayne ^b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Migraine; Randomized controlled trial

Indexed keywords

ANALGESIC AGENT; PLACEBO; RIBOFLAVIN; VITAMIN B COMPLEX;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; MALE; MIGRAINE; NAUSEA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; URINE COLOR; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADOLESCENT; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIGRAINE DISORDERS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RIBOFLAVIN; VITAMIN B COMPLEX;

EID: 54549084688     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808318053     Document Type: Article

References (16)

1. Milovanovic M., Jarebinski M., Martinovic Z. Prevalence of primary headaches in children from Belgrade, Serbia. Eur J Paediatr Neurol. 2007;11:136-141.
2. Lewis D., Ashwal S., Hershey A., Hirtz D., Yonker M., Silberstein S. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215-2224.
3. Montagna P., Cortelli P., Monari L., et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology. 1994;44:666-669.
4. Watanabe H., Kuwabara T., Ohkubo M., Tsuji S., Yuasa T. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology. 1996;47:1093-1095.
5. Schoenen J., Jacquy J., Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: A randomized controlled trial. Neurology. 1998;50:466-470.
6. Schoenen J., Lenaerts M., Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: Results of an open pilot study. Cephalalgia. 1994;14:328-329.
7. Sändor PS, Äfra J., Ambrosini A., Schoenen J. Prophylactic treatment of migraine with β-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials. Headache. 2000;40:30-35.
8. Boehnke C., Reuter U., Flach U., Schuh-Hofer S., Einhäupl KM, Arnold G. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur J Neurol. 2004;11:475-477.
9. Maizels M., Blumenfeld A., Burchette R. A combination of riboflavin, magnesium and feverfew for migraine prophylaxis: A randomized trial. Headache. 2004;44:885-890.
10. Panetta J., Smith LJ, Boneh A. Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases. J Inherit Metab Dis. 2004;27:487-498.
11. Scholte HR, Busch HFM, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP Riboflavin-responsive complex 1 deficiency. Biochim Biophys Acta. 1995;1271:75-83.
12. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia. 2004;24:1-160.
13. International Headache Society Clinical Trials Subcommittee. Committee members: Tfelt-Hansen P., Block G., Dahlof C., et al. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
14. Victor S., Ryan SW Drugs for preventing migraine headaches in children. Cochrane Database Syst Rev. 2003;(4):CD002761. doi:10.1002/ 14651858.CD002761.
15. van der Kuy PHM, Lohman Jjhm. A quantification of the placebo response in migraine prophylaxis. Cephalalgia. 2002;22:265-270.
16. Eikermann A., Diener HC Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. Cephalalgia. 2003;23:344-347.